3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Phase 1
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
3
Endocrine
3
Thoracic
2
Plasma cell
2
Other hematologic neoplasm
2
Myeloid
2
Gynecologic
2
Gastrointestinal
2
CNS
2
Lymphoid
1
Dermatologic
1
Conditions
Myelodysplastic Syndromes
19
Leukemia, Myeloid, Acute
17
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
12
Leukemia
8
Hematologic Neoplasms
6
Anemia, Refractory, with Excess of Blasts
6
Lymphoma
5
Primary Myelofibrosis
4
Neoplasms
4
Multiple Myeloma
4
Mastocytosis
4
Leukemia, Myelomonocytic, Chronic
4
Leukemia, Myeloid, Chronic-Phase
4
Leukemia, Myeloid, Accelerated Phase
4
Leukemia, Biphenotypic, Acute
4
Graft vs Host Disease
4
Lymphoma, Non-Hodgkin
3
Thyroid Carcinoma, Anaplastic
2
Thyroid Cancer, Papillary
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Myeloproliferative Disorders
2
Melanoma
2
Mastocytosis, Systemic
2
Lymphohistiocytosis, Hemophagocytic
2
Leukemia, Myelomonocytic, Acute
2
Laryngeal Neoplasms
2
Glioma
2
Interventions
trametinib
1
dabrafenib
1
cobimetinib
1
Vemurafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Thyroid Carcinoma, Anaplastic
×
Myeloid
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled